How to Increase Albumin in Decompensated Cirrhosis
Administer intravenous albumin infusion in specific clinical scenarios where it has proven benefit—you cannot meaningfully "increase" endogenous albumin production in decompensated cirrhosis, so the therapeutic strategy is exogenous albumin replacement at appropriate doses and timing.
Understanding the Core Principle
The liver's synthetic function is severely impaired in decompensated cirrhosis, making endogenous albumin production inadequate. The approach is therefore replacement therapy with IV albumin in evidence-based clinical situations, not attempts to stimulate production 1.
Established Indications for IV Albumin (Guideline-Supported)
Large-Volume Paracentesis
Administer 20-25% IV albumin at 6-8 g per liter of ascites removed when >5 L is drained 2. This prevents post-paracentesis circulatory dysfunction (PICD), which albumin reduces significantly (OR 0.38) compared to other volume expanders 3. For patients with hypotension, renal insufficiency, or electrolyte abnormalities, consider albumin even for smaller volume removals 2.
- The mechanism: albumin expands effective arterial blood volume and prevents the hemodynamic collapse that follows rapid fluid shifts
- Dose: 6-8 g/L of fluid removed for volumes >5 L 1, 2
- In patients with acute-on-chronic liver failure (ACLF), use this dose regardless of volume removed 1
Spontaneous Bacterial Peritonitis (SBP)
IV albumin may be considered in SBP patients to prevent acute kidney injury and hepatorenal syndrome 1. The traditional dosing is 1.5 g/kg on day 1 and 1 g/kg on day 3, though recent evidence suggests lower doses (20 g/day for 5 days) may achieve similar outcomes in resource-limited settings 4.
- This reduces progression to AKI and improves short-term survival 5
- The benefit is most pronounced in patients at higher risk of renal dysfunction
Hepatorenal Syndrome (HRS-AKI)
Albumin serves as the therapeutic backbone when combined with vasoconstrictors (terlipressin or midodrine/octreotide) for HRS reversal 5. It enhances vasoconstrictor efficacy and improves renal recovery rates.
Acute Kidney Injury (Non-HRS)
Current practice supports albumin as part of an initial volume challenge to aid diagnosis and potentially promote renal recovery, though timing varies among guidelines 5.
What NOT to Do
Do not use albumin in patients with uncomplicated ascites (hospitalized or outpatient) without the specific indications above 1. This is explicitly stated in guidelines and represents inappropriate resource utilization.
Emerging Evidence: Long-Term Albumin Therapy
Recent data suggest long-term albumin administration (typically weekly infusions) may modify disease course in decompensated cirrhosis by:
- Reducing hyponatremia (OR 0.67) 3
- Preventing complications like ACLF and infections 6
- Improving survival and reducing hospitalization rates 7, 6
However, this remains investigational and is not yet standard practice 7, 8. The optimal dose, duration, and patient selection criteria are undefined. Spanish experts prioritize it for patients with difficult-to-control ascites (89.3%) and renal impairment (55.2%), but institutional barriers limit implementation 8.
Practical Dosing Algorithm
- LVP >5 L: 6-8 g albumin per liter removed
- SBP: 1.5 g/kg day 1, then 1 g/kg day 3 (or 20 g/day × 5 days if cost-limited)
- HRS-AKI: Combine with vasoconstrictors per protocol
- Hyponatremia management: Consider albumin based on volume assessment in severe/symptomatic cases 2
Safety Considerations
Albumin is generally safe but monitor for:
- Fluid overload and pulmonary edema (most common concern) 1
- Dose-dependent cardiac risk in advanced disease 8
- Hypotension/tachycardia, nausea/vomiting (uncommon) 1
These risks are manageable and should not prevent use in appropriate indications.
Key Pitfalls to Avoid
- Using albumin for uncomplicated ascites: No benefit, wastes resources 1
- Substituting other plasma expanders for albumin in LVP: Albumin is superior for preventing PICD 3
- Delaying albumin in SBP: Early administration prevents renal complications 5
- Attempting to "boost" endogenous production: This is not physiologically feasible in decompensated cirrhosis
The evidence strongly supports albumin as a replacement therapy in specific acute scenarios rather than a general strategy to increase serum albumin levels 1, 2, 5.